Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,836,320
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.81
  • Price/Sales 4.76
  • Price/Cash Flow 12.39
  • Price/Book 5.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.15
  • Number of Estimates 6
  • High Estimate 1.18
  • Low Estimate 1.11
  • Prior Year 1.11
  • Growth Rate Est. (year over year) +3.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.91 +4.70%
on 09/05/18
71.57 -0.66%
on 09/21/18
+1.93 (+2.79%)
since 08/21/18
3-Month
59.80 +18.90%
on 06/27/18
71.57 -0.66%
on 09/21/18
+9.92 (+16.21%)
since 06/21/18
52-Week
52.83 +34.58%
on 04/03/18
71.57 -0.66%
on 09/21/18
+5.50 (+8.38%)
since 09/21/17

Most Recent Stories

More News
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda

Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.

GALT : 6.53 (-5.77%)
MRK : 71.10 (+0.45%)
PCRX : 50.50 (-2.88%)
BSTC : 58.52 (+1.35%)
Watch for Shares of Merck & Co (MRK) to Approach Resistance at $71.33

Merck & Co (NYSE:MRK) has opened bullishly above the pivot of $70.55 today and has reached the first level of resistance at $71.06. Analysts will be watching for a cross of the next upside pivot targets...

MRK : 71.10 (+0.45%)
Entera Bio Appoints Dr. Arthur Santora as Chief Medical Officer

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II, MD, PhD as its new Chief Medical Officer, effective immediately.

MRK : 71.10 (+0.45%)
ENTX : 5.24 (-0.19%)
Global DNA Vaccine Market Outlook 2022 Featuring GlaxoSmithKline's Engerix-B, Twinrix, and Fendrix; Merck's Gardasil, and Recombivax HB; Protein Sciences Corporation's Flublok - ResearchAndMarkets.com

The "Global DNA Vaccine Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

MRK : 71.10 (+0.45%)
GSK : 40.30 (+1.08%)
Dye Sensitized Solar Cells: Market Analysis & Projections to 2024 Featuring Sharp, Peccell Technologies, Oxford Photovoltaics, Merck, G24 Power, and more - ResearchAndMarkets.com

The "Dye Sensitized Solar Cell Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

MRK : 71.10 (+0.45%)
Agenus Closes $15 Million Partial Royalty Monetization With XOMA

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty...

AGEN : 2.00 (-4.76%)
MRK : 71.10 (+0.45%)
Merck Receives Positive CHMP Opinion for DELSTRIGO(TM) (doravirine/lamivudine/tenofovir disoproxil fumarate) and PIFELTRO(TM) (doravirine) in the European Union for the Treatment of HIV-1 Infection

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

MRK : 71.10 (+0.45%)
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

AZN : 37.68 (-0.11%)
MRK : 71.10 (+0.45%)
PFE : 44.06 (+0.71%)
MKGAF : 101.5000 (+0.45%)
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-8201 in Combination with KEYTRUDA® (pembrolizumab) in HER2 Expressing Breast and HER2 Expressing or HER2 Mutant Lung Cancers

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.,...

MRK : 71.10 (+0.45%)
DSNKY : 42.8700 (+1.68%)
Bristol-Myers' MM Drug Empliciti Application Validated by EMA

Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.

CELG : 87.72 (-0.66%)
MRK : 71.10 (+0.45%)
ABBV : 92.26 (-0.45%)
BMY : 62.25 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 71.86
1st Resistance Point 71.48
Last Price 71.10
1st Support Level 70.81
2nd Support Level 70.52

See More

52-Week High 71.57
Last Price 71.10
Fibonacci 61.8% 64.41
Fibonacci 50% 62.20
Fibonacci 38.2% 59.99
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar